Recursion Pharmaceuticals Inc - Class A RXRX

NAS: RXRX | ISIN: DE0007201980 17/05/2024

9,420 USD (-0,95%)

(-0,95%) 17/05/2024

Toon enkel gratis nieuws

1 februari 2023 · Recursion to Participate in Upcoming Investor Conference · Persbericht

26 januari 2023 · Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day · Persbericht

20 december 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

8 november 2022 · Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results · Persbericht

2 november 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

25 oktober 2022 · Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB · Persbericht

13 september 2022 · Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 · Persbericht

1 september 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

18 augustus 2022 · Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum · Persbericht

9 augustus 2022 · Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results · Persbericht

2 augustus 2022 · Recursion to Participate in Upcoming Investor Conference · Persbericht

21 juli 2022 · Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe